PRIVACY NOTICE FOR APPLICANTS
Arrigo Recordati International
Prize for Scientific Research – 2026 Edition
Pursuant to Articles 13 and 14 of Regulation (EU) no. 679/2016 (“GDPR”) and other applicable data protection laws, Recordati Industria Chimica e Farmaceutica S.p.A. has drawn up this document (the “Privacy Notice“) to describe how it processes personal data in relation to applications for the Arrigo Recordati International Prize for Scientific Research – 2026 Edition (the “Initiative”).
For additional processing activities, such as those related to the website https://prize.recordati.com, or participation in the Initiative’s award ceremony, we invite you to consult the relevant privacy notice as provided from time to time.
This Privacy Notice applies to the processing of personal data pertaining to:
(hereinafter jointly referred to as “Data Subjects” or “you”).
If the Applicant submits documentation and information containing personal data of other individuals to apply to the Initiative, the Applicant should provide those individuals with a copy of this Privacy Notice.
The data controller is Recordati Industria Chimica e Farmaceutica S.p.A., a company of the Recordati Group, with registered office at Via Matteo Civitali 1, Milan – Italy (“Recordati” or “Data Controller” or “we”).
The Data Protection Officer of the Recordati Group can be contacted for any privacy issue or question arising or in connection with the processing of personal data at the following email address: groupDPO@recordati.com.
The following personal data will be processed (hereinafter “Personal Data”):
Scientific research data submitted by the shortlisted Applicants, which may include health and other special categories of personal data, is handled by Recordati in a fully anonymized format, ensuring that no individual can be identified directly or indirectly.
Your Personal Data will be processed for the following purpose with the corresponding legal basis indicated:
# | Purpose of the processing | Legal basis for the processing | |
1. | To collect and process your application, including sharing data with the Reviewing Committee (as defined below) for evaluation and selection of the winner of the Initiative, as well as to manage communications and follow ups with the Applicants or other Data Subjects, as appropriate. | · performance of a contract with you, namely in order to follow up to the request of the Data Subject or to perform a submission agreement between Recordati and the Data Subject. | All categories of Personal Data. |
· |
Provision of your Personal Data is mandatory and in failure you will not be able to submit your application and participate in the Initiative.
The processing of your Personal Data will be based on the principles of lawfulness, fairness, transparency, proportionality and minimization and will be carried out electronically, using suitable tools to guarantee the security and confidentiality of your data.
Your Personal Data will be retained for different terms, depending on whether the Applicant is awarded the Initiative prize. In this case, Personal Data will be retained for a period of ten years following the conferral of the Initiative’s prize, unless such Personal Data are relevant for archival and historical purposes; in such case, they will be included in our archives and retained for as long as necessary to achieve the intended purposes.
For Applicants who are not selected for the Initiative prize, Personal Data will be maintained for one year after the prize has been awarded. In case of incomplete or late applications,
Your Personal Data may be accessed by Recordati employees and collaborators, specifically designated as persons authorised to process it, where necessary for the pursuit of the purposes described above.
Your Personal Data will be shared with the persons in charge to assess your application (the “Reviewing Committee”) in their capacity as independent data controllers. In addition, your Personal Data may also be communicated or made accessible to consultants and third-party suppliers of technical or organizational services, functional to the purposes described above, in their capacity as our data processors, specifically designated and instructed on the basis of a specific contract.
Your Personal Data may also be accessed by authorities or other public bodies by virtue of legal provisions or secondary or EU legislation, in their capacity as independent data controllers, for their respective institutional purposes.
Personal Data will be transferred outside the European Economic Area[1], . For the latter,
The Data Controller informs you that you can exercise, at any time, the following rights by contacting the Data Controller or the DPO at the addresses indicated above:
The exercise of the above rights is not subject to any formal constraint and is free of charge. The Data Controller may ask you to verify your identity before taking further action following your request to exercise the rights referred to above.
You may also lodge a complaint with the competent Supervisory Authority (in particular in the Member State of your habitual residence, place of work or place of the alleged violation), if you are of the opinion that your Personal Data are being processed in such a way as to result in violations of privacy legislation. You may also contact the Supervisory Authority if the exercise of your rights is subject to delay, limitation or exclusion by the Data Controller.
You may also contact the relevant supervisory authority if the exercise of your rights is subject to delay, limitation or exclusion by the data controller.
In order to facilitate the exercise of the right to lodge a complaint, please find below the name and contact details of the supervisory authority in Italy:
The name and contact details of the supervisory authorities of the European Union are available at the following link: Our Members | European Data Protection Board (europa.eu).
If Legislative Decree No. 196/2003 as subsequently amended and supplemented by Legislative Decree no. 101/2018 (“Italian Privacy Code”) applies to the processing of your Personal Data, in case of Data Subject’s death, the aforesaid rights relating to their Data may be exercised by anyone who has a personal interest, or acts to protect the Data Subject as its representative, or for family reasons worthy of protection pursuant to article 2-terdecies of the Italian Privacy Code. Data Subjects may expressly prohibit the exercise by its assignees of some of the rights above by written notice to be sent to Recordati as described above, without prejudice to their right to withdraw or modify such expressed intention later on according to the same procedure.
This Privacy Notice is valid from the date of effectiveness provided below. However, the Privacy Notice may subsequently be updated or integrated, from time to time, also as consequence of possible subsequent amendments and/or integrations of the applicable laws. Changes will be notified in advance and Data Subjects will be able to consult the constantly updated version of this Privacy Notice on Recordati’s website.
[1] The European Economic Area (EEA) consists of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Republic of Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.
Sandra Strauss is Professor of Medical and Teenage Young Adult (TYA) Oncology and a Consultant Medical Oncologist. She specialises in the systemic treatment of bone and soft tissue sarcoma and leads the clinical service at University College London Hospital, part of the London Sarcoma Service, one of the largest sarcoma services in Europe.
Her academic post is based within University College London and is focused on translational and clinical research to develop novel therapies for sarcoma patients. She has over 15 years’ experience as a chief and principal investigator for international and national clinical trials. She chairs the executive committee of the EuroEwing consortium (EEC), a pan-European collaboration that has brought together clinicians, scientists and patient advocates to improve outcome for patients with Ewing sarcoma, conducting practice-changing clinical trials with focused translational research. She chairs the UK NCRI Sarcoma Clinical Studies Group Bone Subgroup and is the current sarcoma track chair of European Society of Medical Oncology (ESMO).
She is an executive Committee member of FOSTER (Fight Osteosarcoma through European Research), a scientific committee member of SIOPE, the European Society of paediatric oncology, and ESMO rare cancer and sarcoma annual meeting.
She is an executive member of the Hibiscus Harmonization International Bone Sarcoma Consortium (HIBiSCus), a member of European Organisation for Research and Treatment of Cancer (EORTC) and Innovative Therapies for Children with Cancer (ITCC) consortium.
Alice L. Yu, M.D., Ph.D. is an Academician of Academia Sinica in Taiwan. She has been a Distinguished Chair Professor of the Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital & Chang Gung University since 2013 and Professor Emeritus of Pediatrics at the University of California in San Diego.
From 2003 to May 2013, Dr. Yu served as a Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. Prior to this, she was the Chief of Pediatric Hematology Oncology at the University of California in San Diego. She has been a long-time member of the Children’s Oncology Group in the United States, serving on the Steering Committee of Neuroblastoma. She is also a member of various scientific committees and associations.
As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target carbohydrate antigen. Treatment with anti-GD2 has since become standard of care for high risk neuroblastoma. For another prevalent tumor-associated glycan, Globo H, her group has demonstrated the adverse impact of its expression on the clinical outcome of patients with hepatoma, cholangiocarcinoma and gallbladder cancer. She has also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and an angiogenic factors, providing rationales for the development of Globo H-targeted immunotherapeutics.
She received the Lifetime Achievement Award from the Advances in Neuroblastoma Research Association in 2025, Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium, USA in 2016, The 55th Academic Award from the Ministry of Education, The 19th Wang Min-Ning Memorial Award for Outstanding Contribution to the Development Medical Science and Technology, National Health and Society, Year 2000 “Key to Life” Award from Leukemia & Lymphoma Society, USA, etc.
Dean for Genetics and Genomic Medicine, Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences, The Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Robert J. Desnick is Dean for Genetic and Genomic Medicine and Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai.
In 1977, he joined the Mount Sinai faculty as the Arthur J. and Nellie Z. Cohen Professor of Pediatrics and Genetics, and Chief of Medical and Molecular Genetics. From 1993-2011, he was the first Chairman of the Department of Genetics and Genomic Sciences at Mount Sinai. In 2011 he became the Dean for Genetics and Genomic Medicine.
Dr. Desnick’s research interests include lysosomal storage diseases (LSDs) and the inborn errors of heme biosynthesis, the porphyrias, and in particular, their treatment.
His research efforts led to the Federal Drugs Administration (FDA) – and European Medicine Agency (EMA) – approval of enzyme replacement therapy (ERT) for Fabry disease (Fabrazyme) and on-going ERT clinical trials (FDA “Breakthrough” status) for Niemann- Pick B disease, both in partnership with Genzyme. In addition, he was a scientific founder of Amicus Therapeutics (NASDAQ; FOLD), which is developing oral pharmacologic chaperone therapy for Fabry disease (EMA-approved in 2016), Pompe disease, and other disorders. Currently, his laboratory is using gene editing technology to engineer gene therapy in the mouse model of Fabry disease with Sangamo Therapeutics.
Arrigo Recordati believed research was the most powerful asset for the pharmaceutical industry. He became head of the family business in 1951, at the age of 23, and transformed the family pharmaceutical laboratory employing 325 people into an international company listed since 1984 on the Italian Stock Exchange.
Arrigo Recordati’s remarkable life came to a premature end at the age of 71, in 1999.
Under his direction, in 1953 the company’s headquarters and pharmaceutical plant moved from Correggio, a small town in the Emilia region of Italy, to Milan, the capital of Italian business. During this time Arrigo Recordati provided the company with a stronger competitive advantage by updating its research facilities with advanced pharmacological laboratories.
In the 1950s and 60s, Arrigo Recordati relied on two strong beliefs: scientific research and internationalization. To maximize the results of Recordati research, he established subsidiaries in Brazil and Mexico. Arrigo Recordati also fostered a close relationship with the United States, signing among other things a strategic partnership agreement with Syntex Corporation (acquired by Roche Corporation in 1990) – at that time a company involved in cutting-edge research on the synthesis of steroid hormones.
Arrigo Recordati strongly believed in the power of scientific research to drive the growth of the pharmaceutical industry and provide products beneficial to public health and individual well-being. Efloxate (1955), a coronary vasodilator for the treatment of cardiovascular disease, was the first compound to originate from Recordati’s research laboratories during Arrigo Recordati’s leadership. Other original molecules developed and marketed during his leadership include: dimefline (1958), a respiratory analeptic, flavoxate (1957), a urinary antispasmodic, tibezonium iodide (1971), an oral antiseptic, fenticonazole (1978), an antimycotic and lercanidipine (1984), a calcium channel blocker for the treatment of hypertension. In particular, flavoxate was the first original New Chemical Entity developed by an Italian company to be approved by FDA (Federal Drug Administration) in the United States.
Arrigo Recordati also believed that even small companies – if managed with vigor and imagination – can compete effectively in the pharmaceutical arena. In 1984 Recordati was listed on the Italian Stock Exchange, completing its transformation from a small, family-run operation to a modern, professional, publicly listed company.
After 48 years of intense and challenging leadership, Arrigo Recordati passed away, leaving a solid, international business projected into the future.